Medicare’s addiction to disconnected drug prices
Ben LinkGeneric, Medicare, PBM, Part D, AWP, dispensing fee, Transparency in Coverage, Suboxone, Buprenorphine-naloxone, opioid use disorder, addiction treatment, NADAC, Medicaid
How Mark Cuban reveals hidden costs of variable drug prices in Medicare
Ben LinkGeneric, Medicare, PBM, Mark Cuban, Cost Plus Drugs, Part D, imatinib, Costco, CVS, Cigna, UnitedHealth
Money from Sick People Part IV: Paying a Premium for Drug Pricing Irregularity
Ben LinkList prices, WAC, Insulin, Lantus, PBM, Humalog, Rutledge v PCMA, diabetes, Inflation Reduction Act, Apidra, Novolog, Levemir, Medicare, Part D
Medicare hits $200 billion in gross drug spend: Who gets the blame?
Ben LinkMedicare, Part D, Brand drugs, Generic drugs, Specialty, DIR fees, Rebates, PBM, Eliquis, Revlimid, Xarelto, Januvia, Trulicity, Imbruvica, Lantus, Jardiance, Humira, Ibrance, NADAC, atorvastatin, WAC
International reference pricing: Discounts Down Under far surpass U.S. drug price concessions
Ben LinkAustralia, International pricing, PBM, NADAC, Eliquis, Rebates, Advair, Fluticasone, Gleevec, Imatinib, Part D, Part B, Aetna, Albuterol
The Flawed Design of Medicare Part D: A Copaxone Case Study
Ben LinkCopaxone, glatiramer, Medicare, Part D, PBM, specialty drugs, Gleevec, ACA, Drug prices, Teva, Mylan, Sandoz, Deductible, Rebates, DIR fees
